Table 1.
MAb | Clone | [MAb] (µg/mL) | ∆Pmax (mP) 1 | |||
---|---|---|---|---|---|---|
T2-FL (Dilution 1:3600) 2 |
HT2-FL1a (Dilution 1:3000) 2 |
HT2-FL1b (Dilution 1:400) 2 |
HT2-FL2 (Dilution 1:3600) 2 |
|||
Anti-T2G | 1–2 | 190 | 138 3 | - | 59 | 57 |
1–3 | 40 | 280 3 | 39 | 262 3 | 159 3 | |
1–4 | 104 | 225 3 | 28 | 253 3 | 176 3 | |
2–5 | 89 | 116 | 53 | 246 2 | 27 | |
2–11 | 118 | 144 3 | 18 | 50 | 18 | |
2–13 | 134 | 191 3 | 23 | 28 | 19 | |
2–16 | 90 | 200 3 | 37 | 82 | 21 | |
2–17 | 120 | 129 | 27 | 156 3 | 18 | |
2–21 | 132 | 159 3 | 22 | 14 | 16 | |
2–44 | 155 | 176 3 | 133 3 | 246 3 | 49 | |
Anti-T2 | 1 | 6 | 282 3 | 217 3 | 93 | 111 |
Anti-HT2 | H10-A10 | 8 | 205 3 | 230 3 | 122 | 20 |
1 ∆Pmax = mPMAb − mPtracer; −∆Pmax < 10mP; 2 Optimised dilution (v/v) of the stock solutions providing a total fluorescence intensity equal to 3-fold the blank signal measured for PBS-A; 3 selected antibody/tracer combinations.